Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?

Ann Rheum Dis. 2021 Feb;80(2):e19. doi: 10.1136/annrheumdis-2020-217570. Epub 2020 Apr 21.

Authors

Sergey Moiseev¹, Sergey Avdeev², Michail Brovko³, Pavel Novikov³, Victor Fomin⁴

Affiliations

¹ Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia [email protected].
² Clinic of Pulmonology, Sechenov First Moscow State Medical University, Moscow, Russia.
³ Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia.
⁴ Vinogradov Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia.

PMID: 32317315
DOI: 10.1136/annrheumdis-2020-217570

No abstract available

Keywords: autoimmune diseases; hydroxychloroquine; lupus erythematosus, systemic.

Publication types

Letter
Comment

MeSH terms

Antimalarials*
Antiviral Agents* / therapeutic use
COVID-19*
Chloroquine
Humans
Hydroxychloroquine / therapeutic use
Pandemics
SARS-CoV-2

Substances

Antimalarials
Antiviral Agents
Hydroxychloroquine
Chloroquine